Back to Browse Journals » Cancer Management and Research » Volume 1

Bortezomib in the management of multiple myeloma

Authors Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, et al

Published Date September 2009 Volume 2009:1 Pages 107—117

DOI http://dx.doi.org/10.2147/CMAR.S4555

Published 8 September 2009

Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, Robert Schlossman, Dharminder Chauhan, Nikhil Munshi, Irene Ghobrial, Nicole Carreau, Kenneth C Anderson, Paul G Richardson

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

Abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by clonal expansion of plasma cells within the bone marrow, the presence of a serum and/or urine monoclonal protein, lytic bone lesions, and anemia. On a cellular level, the disease is characterized by complex interactions between tumor cells and the surrounding bone marrow microenvironment. Understanding of the relationship between malignant plasma cells and the microenvironment has sparked ongoing efforts to develop targeted therapeutic agents for treatment of this disease. The successful development of the first-in-class small-molecule proteasome inhibitor bortezomib occurred as a result of these efforts. This review focuses on the rationale for bortezomib therapy in the treatment of patients with newly diagnosed and relapsed MM, important treatment-related side effects, and future directions for use of bortezomib and other, emerging proteasome inhibitors.

Keywords: multiple myeloma, bortezomib, stem cell transplantation, peripheral neuropathy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy

Paul Richardson, Constantine Mitsiades, Jacob Laubach, et al

Core Evidence 2009, 4:215-245

Published Date: 17 November 2009

Readers of this article also read:

Uptake of bright fluorophore core-silica shell nanoparticles by biological systems

Zane A, McCracken C, Knight DA, Young T, Lutton AD, Olesik JW, Waldman WJ, Dutta PK

International Journal of Nanomedicine 2015, 10:1547-1567

Published Date: 20 February 2015

Value of portal venous system radiological indices in predicting esophageal varices

Gaduputi V, Patel H, Sakam S, Neshangi S, Ahmed R, Lombino M, Chilimuri S

Clinical and Experimental Gastroenterology 2015, 8:89-93

Published Date: 9 February 2015

Echocardiographic assessment of left ventricular function in thyrotoxicosis and implications for the therapeutics of thyrotoxic cardiac disease

Anakwue RC, Onwubere BJ, Ikeh V, Anisiuba B, Ike S, Anakwue AC

Therapeutics and Clinical Risk Management 2015, 11:189-200

Published Date: 5 February 2015

Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer

Zhao XJ, Chen Q, Liu W, Li YS, Tang HB, Liu XH, Yang XL

International Journal of Nanomedicine 2015, 10:257-270

Published Date: 30 December 2014

Photothermal cancer therapy using graphitic carbon–coated magnetic particles prepared by one-pot synthesis

Lee HJ, Sanetuntikul J, Choi ES, Lee BR, Kim JH, Kim E, Shanmugam S

International Journal of Nanomedicine 2015, 10:271-282

Published Date: 30 December 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Newer agents in antiplatelet therapy: a review

Yeung J, Holinstat M

Journal of Blood Medicine 2012, 3:33-42

Published Date: 25 June 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010